Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search
Fullscreen

For citation:


Avxentyev N.A., Lubennikova E.V., Frolov M.Y. Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2019;12(4):279-290. (In Russ.) https://doi.org/10.17749/2070-4909.2019.12.4.279-290

Views: 47


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)